UACC-893Homo sapiens (Human)Cancer cell line

Also known as: University of Arizona Cell Culture-893, UACC893, UACC 893

🤖 AI SummaryBased on 15 publications

Quick Overview

Human breast cancer cell line with known genetic alterations and drug sensitivity profiles.

Detailed Summary

UACC-893 is a human breast cancer cell line derived from a primary tumor. It is characterized by specific genetic mutations and has been used in studies to investigate cancer biology and drug responses. The cell line has been part of large-scale genomic and proteomic analyses, contributing to the understanding of breast cancer heterogeneity and therapeutic targets. Research on UACC-893 has focused on its molecular profiles, including gene expression, mutations, and protein expression, which are critical for developing targeted therapies. The cell line's data is part of several comprehensive cancer cell line databases, providing valuable insights into cancer mechanisms and potential treatment strategies.

Research Applications

Cancer biology researchDrug sensitivity profilingGenomic and proteomic analysisTargeted therapy development

Key Characteristics

Genetic mutations identifiedDrug response data availablePart of large-scale cancer cell line studies
Generated on 6/17/2025

Basic Information

Database IDCVCL_1782
SpeciesHomo sapiens (Human)
Tissue SourceBreast[UBERON:UBERON_0000310]

Donor Information

Age57
Age CategoryAdult
SexFemale
Racecaucasian
Subtype FeaturesHER2+

Disease Information

DiseaseInvasive breast carcinoma of no special type
LineageBreast
SubtypeBreast Invasive Lobular Carcinoma
OncoTree CodeILC

DepMap Information

Source TypeATCC
Source IDACH-000554_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Arg342Ter (c.1024C>T)Homozygous-PubMed=29970484
MutationSimplePIK3CAp.His1047Arg (c.3140A>G)Unspecified-PubMed=25926053, PubMed=20570890
MutationSimpleCDH1p.His233Gln (c.699C>G)Homozygous-PubMed=19593635

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
11,12
D13S317
13
D16S539
9,13
D18S51
17,18
D19S433
13,13.1
D21S11
28,30.2
D2S1338
19,25
D3S1358
16
D5S818
12
D7S820
11
D8S1179
13
FGA
22,25
Penta D
9,12
Penta E
13,17
TH01
6,9.3
TPOX
8
vWA
16,17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.

Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.

OncoImmunology 3:e954893.1-e954893.12(2014).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Modeling precision treatment of breast cancer.";

Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.

Genome Biol. 14:R110.1-R110.14(2013).

Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.

Harrell J.C., Roman E., Adamo B., Troester M.A., Perou C.M.

Breast Cancer Res. Treat. 142:237-255(2013).

miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.

Martens J.W.M.

Breast Cancer Res. 15:R33.1-R33.17(2013).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues.

Yamamoto S., Oka M., Hirano T., Sasaki K.

BMC Cancer 10:15.1-15.10(2010).

Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.

den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.

Breast Cancer Res. Treat. 121:53-64(2010).

Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.

Pollack J.R.

PLoS ONE 4:E6146-E6146(2009).

Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.

Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.

Breast Cancer Res. Treat. 99:97-101(2006).

Comprehensive copy number profiles of breast cancer cell model genomes.

Shadeo A., Lam W.L.

Breast Cancer Res. 8:R9.1-R9.14(2006).

BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.

van den Ouweland A.M.W., Merajver S.D., Ethier S.P., Schutte M.

Cancer Res. 66:41-45(2006).

The acetyltransferase p300/CBP-associated factor is a p53 target gene in breast tumor cells.

Domann F.E., Futscher B.W.

Neoplasia 6:187-194(2004).

Aberrations of chromosome 8 in 16 breast cancer cell lines by comparative genomic hybridization, fluorescence in situ hybridization, and spectral karyotyping.

Isola J.J.

Cancer Genet. Cytogenet. 126:1-7(2001).

Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping.

Isola J.J., Larsson C.

Genes Chromosomes Cancer 28:308-317(2000).

Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells.

Rice J.C., Massey-Brown K.S., Futscher B.W.

Oncogene 17:1807-1812(1998).

Identification of cryptic sites of DNA sequence amplification in human breast cancer by chromosome microdissection.

Guan X.-Y., Meltzer P.S., Dalton W.S., Trent J.M.

Nat. Genet. 8:155-161(1994).

Establishment of two new cell lines derived from human breast carcinomas with HER-2/neu amplification.

Nagle R.B., Trent J.M.

Br. J. Cancer 63:727-735(1991).

Cell lines from human breast.";

Leibovitz A.

(In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York; USA (1994).